The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease.
Integrative HMP (iHMP) Research Network Consortium. · 2014
Read The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. by Integrative HMP (iHMP) Research Network Consortium. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5109542.txt.
Introduction
The Integrative Human Microbiome Project consortium described its research program in Cell Host and Microbe in 2014. The project is the second phase of the United States National Institutes of Health effort to map the microbes that live on and in people. It moves from cataloging species toward watching how microbes and hosts affect each other over time.
The program follows three groups over time: pregnancies at risk of early birth, people with inflammatory bowel disease, and people developing type 2 diabetes. For each, teams collect many kinds of molecular data from microbes and hosts together, then share the combined sets openly. The aim is a test bed where new models of microbe-host interaction can be tried against rich, long-running records.
Catalog record
| CREATOR | Integrative HMP (iHMP) Research Network Consortium. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Integrative Human Microbiome Project: Dynamic Analysis of Microbiome-Host Omics Profiles during Periods of Human Health and Disease Published in: Cell host & microbe DOI: 10.1016/j.chom.2014.08.014 ABSTRACT Much has been learned about the diversity and distribution of human-associated microbial communities, but we still know little about the biology of the microbiome, how it interacts with the host, and how the host responds to its resident microbiota. The Integrative Human Microbiome Project (iHMP, http://hmp2.org), the second phase of the NIH Human Microbiome Project, will study these interactions by analyzing microbiome and host activities in longitudinal studies of disease-specific cohorts and by creating integrated data sets of microbiome and host functional properties. These data sets will serve as experimental test beds to evaluate new models, methods, and analyses on the interactions of host and microbiome. Here we describe the three models of microbiome-associated human conditions, on the dynamics of preterm birth, inflammatory bowel disease, and type 2 diabetes, and their underlying hypotheses, as well as the multi-omic data types to be collected, integrated, and distributed through public repositories as a community resource. INTRODUCTION The human microbiome is important for human health, behavior, and disease, yet its function and dynamics during healthy and disease states are only partially understood. The first phase of the NIH Human Microbiome Project (HMP, fiscal years 2008–2012, http://www.commonfund.nih.gov/hmp) examined the diversity and composition of the human microbiome to evaluate (1) common patterns of microbial diversity associated with health and (2) whether specific features of the microbiome correlated with specific diseases by analyzing the taxonomic and metagenomic composition of the microbiome in a large healthy cohort and in a set of demonstration projects. These efforts revealed the vast microbial diversity associated with humans and provided new insights into the ecology of the host-microbiome supraorganism (Human Microbiome Project Consortium, 2012a, 2012b). Results from previous human microbiome studies (Dethlefsen et al., 2006; Hooper and Gordon, 2001; Qin et al., 2010; Savage, 1977) and from the first phase of HMP (Human Microbiome Project Consortium, 2012a, 2012b) suggested that taxonomic composition of the microbiomes between subjects within a cohort can sometimes differ significantly, indicating that taxonomic characterization alone may not be sufficient to reveal relationships between the microbiome and specific health or disease states. Interestingly, metabolic pathway reconstructions of the metagenomic data from the HMP healthy cohort study suggested that the microbiomes of healthy subjects may share similarities in their metabolic pathways; this feature may be a key common property of the microbiome within any given cohort (Human Microbiome Project Consortium, 2012b). Further, in some of the HMP Demonstration Projects (http://commonfund.nih.gov/hmp/fundedresearch), analysis of microbiome biological properties, such as community transcripts, proteins, or metabolites, hinted at losses or gains of key microbiome functions associated with particular diseases. The second phase of HMP (or iHMP, Integrative Human Microbiome Project Consortium, fiscal years 2013–2016, http://hmp2.org) will further examine the role of the microbiome in human health and disease through a study of three models of microbiome-related human conditions. These three longitudinal studies focus on (1) pregnancy, including those resulting in preterm birth; (2) gut disease onset, using inflammatory bowel disease (IBD) as a model; and (3) respiratory viral infection and onset of type 2 diabetes (T2D). In each case, subjects will be followed for up to 3 years. Multiple properties of the microbiome, such as phylogenetic composition and associated functional omic data (e.g., transcriptome and/or proteome) will be analyzed. Importantly, host functional changes will also be monitored (e.g., transcriptome, proteome, and/or autoantibody profiles) as well as metabolites originating from both the host and the microbiome so that microbiome and host changes can be simultaneously followed to provide a more comprehensive picture of the dynamic changes that occur during these periods. The studies were selected as exemplary models of microbiome-associated human conditions and therefore should be of broad interest to the research community. These resulting data sets will provide opportunities for new hypotheses to be tested and for evaluating the utility of simultaneously assessing the microbiome and the host biological properties for understanding host-microbiome interactions. DATA DEPOSITION, ACCESS, AND SHARING Primary data (e.g., sequence reads or mass spectrometry profiles) and derived properties (e.g., microbial composition, gene expression and protein levels, and metabolite profiles) will be generated by each project. Table 1 lists the biospecimens and data types to be collected, and the public repositories for the primary data. A glossary for the multi-omic properties is included in Table 2. Primary data will be accessible from public databases such as SRA (genomic sequences, metagenomic sequences, transcript data), GEO (gene expression data), EBI PRIDE (proteomic data), and the Metabolomics Workbench (http://www.metabolomicsworkbench.org/, metabolomic data). Protected data, such as human sequence data and specific clinical metadata, will be deposited in the NCBI dbGaP controlled access database; requests to access these data can be made through dbGaP (https://dbgap.ncbi.nlm.nih.gov). Bacterial strains will be deposited in the HMP reference strain collection at ATCC/BEI. In addition to the public repositories, all nonprotected (i.e., nonhuman) data will also be in structured, study-specific databases hosted by each team. In accordance with HMP policies, all data of sufficiently high quality will be rapidly deposited in public repositories in advance of any iHMP Consortium publication. Analyses will be performed on early data sets from each of the projects; derived data sets used in these analyses will be made available at publication. An iHMP data coordination center (http://hmpdacc.org) will work with the three teams to process common data types in a uniform fashion to optimize data integration across the three studies. A summary of each project as currently proposed and the assays to be executed is presented in the following sections. These clinical studies are under IRB oversight at their respective institutions. All study subjects have been appropriately consented for broad data sharing in open access databases except for protected subject data, which will be deposited in the controlled access database, dbGaP. IHMP STUDY: INTEGRATIVE MULTI-OMIC ANALYSIS OF THE VAGINAL AND RELATED MICROBIOMES IN PREGNANCY, INCLUDING PRETERM BIRTH The annual United States health care costs for newborns with complications exceeds $26 billion (Behrman and Butler, 2007). Worldwide, preterm birth is the leading cause of morbidity and mortality among neonates. Recent decades have seen improved survival of preterm neonates, but the incidence has not decreased. Very preterm births (<32 weeks), which pose the greatest health risks to the infant, are commonly caused by infection and inflammation in the uterine cavity (Goldenberg et al., 2000). Intrauterine infection can cause premature rupture of membranes, preterm labor, and other complications. Evidence is accumulating that the maternal microbiome undergoes significant changes during pregnancy and plays a key role in fetal and infant morbidity associated with health issues, including but not limited to: gestational diabetes, low birth weight, necrotizing enterocolitis, and colic (Aagaard et al., 2012; de Weerth et al., 2013; Koren et al., 2012; Prince et al., 2014; Romero et al., 2014a, 2014b). Hence, the maternal microbiome likely plays a critical but largely undefined role in the health of the pregnant woman and her fetus. Project Description The goal of the Multi-Omic Microbiome Study: Pregnancy Initiative (http://vmc.vcu.edu/momspi) is to study the dynamic changes in the vaginal and related microbiomes and associated host responses during normal pregnancy, in the development of adverse outcomes of pregnancy, and